Tian Peng, Liu Yue, Li Zhi-Jun, Xu Gui-Jun, Ma Xin-Long
Department of Traumatic Orthopedics, Tianjin Hospital, Tianjin, China.
Department of Spine Surgery, Tianjin Hospital, Tianjin, China.
Front Surg. 2021 May 21;8:668551. doi: 10.3389/fsurg.2021.668551. eCollection 2021.
We performed a meta-analysis to evaluate the efficacy and safety of zoledronic acid combined with percutaneous kyphoplasty (PKP) in treating osteoporotic vertebral compression fractures (OVCFs). Eligible scientific articles published prior to July 2020 were retrieved from the PubMed, Springer, ScienceDirect, and Cochrane Library databases. The statistical analysis was performed with RevMan 5.1. Three randomized controlled trials (RCTs) and 2 non-RCTs met the inclusion criteria. The present meta-analysis revealed that zoledronic acid combined with PKP is associated with a higher BMD, a better quality of life, less severe low back pain, and fewer additional vertebral body fractures than is percutaneous vertebral augmentation alone. Compared with PKP only, zoledronic acid combined with percutaneous vertebral augmentation is beneficial for OVCFs.
我们进行了一项荟萃分析,以评估唑来膦酸联合经皮椎体后凸成形术(PKP)治疗骨质疏松性椎体压缩骨折(OVCFs)的疗效和安全性。从PubMed、Springer、ScienceDirect和Cochrane图书馆数据库中检索了2020年7月之前发表的符合条件的科学文章。使用RevMan 5.1进行统计分析。三项随机对照试验(RCT)和两项非RCT符合纳入标准。本荟萃分析表明,与单纯经皮椎体强化术相比,唑来膦酸联合PKP可提高骨密度、改善生活质量、减轻严重腰痛并减少额外椎体骨折。与单纯PKP相比,唑来膦酸联合经皮椎体强化术对OVCFs有益。